10x Genomics, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 115,195,009 | $2 | $1,839,397 | $(1,029,321) | $(4,335) | $805,743 |
| Issuance of Class A common stock related to equity awards | 3,900,353 | — | 19,483 | — | — | 19,483 |
| Stock-based compensation | — | — | 167,010 | — | — | 167,010 |
| Net loss | — | — | — | (255,099) | — | (255,099) |
| Other comprehensive income | — | — | — | — | 3,906 | 3,906 |
| Balance as of December 31, 2023 | 119,095,362 | 2 | 2,025,890 | (1,284,420) | (429) | 741,043 |
| Issuance of Class A common stock related to equity awards | 3,196,475 | — | 10,914 | — | — | 10,914 |
| Stock-based compensation | — | — | 140,868 | — | — | 140,868 |
| Net loss | — | — | — | (182,627) | — | (182,627) |
| Other comprehensive loss | — | — | — | — | (64) | (64) |
| Balance as of December 31, 2024 | 122,291,837 | 2 | 2,177,672 | (1,467,047) | (493) | 710,134 |
| Issuance of Class A common stock related to equity awards | 4,299,500 | — | 6,803 | — | — | 6,803 |
| Issuance of Class A common stock for acquisition of assets | 1,099,992 | — | 13,541 | — | — | 13,541 |
| Stock-based compensation | — | — | 108,674 | — | — | 108,674 |
| Net loss | — | — | — | (43,544) | — | (43,544) |
| Other comprehensive income | — | — | — | — | 718 | 718 |
| Balance as of December 31, 2025 | 127,691,329 | $2 | $2,306,690 | $(1,510,591) | $225 | $796,326 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.